GlassScriptPhysician profile
Joseph K Carrozza
NPI 1912094780
$3,938.01
in general payments reported to CMS, 2019-2025
20 companies · $1,355 in 2025
The $1,355 reported for 2025 was more than what 89% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $397 · 2020: $22.62 · 2022: $301 · 2023: $657 · 2024: $1,205 · 2025: $1,355.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,217.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,216.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,256.62 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Astrazeneca Pharmaceuticals LP | $937.28 | 2022-2025 | Airsupra, Breztri, Farxiga |
| Abbvie INC. | $474.68 | 2023-2025 | Ubrelvy |
| Novo Nordisk INC | $418.16 | 2023-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $239.01 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $103.06 | 2024-2025 | Otezla, Repatha, Repatha |
| Merck Sharp & Dohme LLC | $94.98 | 2022-2023 | Steglatro, Belsomra |
| Lundbeck LLC | $57.36 | 2025 | Rexulti |
| Tandem Diabetes Care, INC. | $52.71 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Dexcom, INC. | $43.73 | 2025 | Dexcom G6 Transmitter |
| Pfizer INC. | $39.22 | 2025 | |
| Rhythm Pharmaceuticals, INC. | $35.60 | 2025 | Imcivree |
| Astellas Pharma US INC | $32.17 | 2024 | Veozah |
| Neurocrine Biosciences, INC. | $31.44 | 2025 | |
| Exact Sciences Corporation | $30.23 | 2024 | Cologuard Collection Kit |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $23.96 | 2025 | Xifaxan |
| Antares Pharma, INC. | $19.51 | 2025 | Xyosted |
| Sequel Med Tech, LLC | $18.10 | 2025 | Twiist |
| Renalytix Ai, INC. | $17.11 | 2025 | Kidneyintelx Blood Collection Convenience Kit |
| Sanofi-Aventis U.S. LLC | $13.08 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Carrozza listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.